# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
HC Wainwright & Co. analyst Emily Bodnar reiterates Femasys (NASDAQ:FEMY) with a Buy and maintains $12 price target.
Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide wit...
- Reuters